Evidence map›Paper›PMID 41309625›Full record

ArticleNPJ Parkinson's disease2025

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.

Roshni Jaffery, Yuhang Zhao, Sarfraz Ahmed, Jackson G Schumacher, Jae Ahn, Leilei Shi, Yujia Wang, Yukun Tan, Jiayin Zhang, Ken Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Integrated Biofluid Proteomics Identified Dynamic Functional Biomarkers ofmedRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Roshni Jaffery *Department of Biology and Biochemistry, University of Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4128-345X
Yuhang Zhao *Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0009-0000-9976-3478
Sarfraz AhmedAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0001-5879-0461
Jackson G SchumacherAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0009-0000-4227-4710
Jae AhnAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0002-9508-4301
Leilei ShiAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0002-8895-1403
Yujia WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5264-521X
Yukun TanDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6368-8653
Jiayin ZhangDepartment of Neurology, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ken ChenAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0003-4013-5279
Hussein TawbiAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0003-1942-851X
Jian WangAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0001-7104-0673
Michael A SchwarzschildAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID http://orcid.org/0000-0001-6019-8280
Weiyi PengDepartment of Biology and Biochemistry, University of Houston, Houston, TX, USA. wpeng2@Central.uh.edu.ORCID http://orcid.org/0000-0002-7785-6240
Xiqun ChenAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA. xchen17@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-8582-8891

Funding

MC1R Basis of Melanoma-Parkinson's Link and Neuroprotective Potential of MC1RR01NS102735 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2018 to 2022
$1.8M
Aligning Science Across Parkinson's ASAP-000312NIH HHS R01NS102735NINDS NIH HHS R01 NS102735
6 · The paper itself

Abstract

Mutations in LRRK2, a leading genetic cause of Parkinson's disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples (n = 651) and matched CSF samples (n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.

Identifiers

PMID41309625
PMCPMC12749785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.